Efficacy of Rapamycin for Refractory Hemangioendotheliomas in Maffucci's Syndrome

被引：24

作者：

Riou, Stephanie ^{[1
]}

Morelon, Emmanuel ^{[2
]}

Guibaud, Laurent ^{[3
,4
]}

Chotel, Franck ^{[3
,4
]}

Dijoud, Frederique ^{[3
,4
]}

Marec-Berard, Perrine ^{[1
]}

机构：

[1] Inst Hematol Oncol Pediat, Lyon, France

[2] Univ Lyon, Hosp Civils Lyon, Hop Edouard Herriot,Lab Immun Infect & Vaccinat, INSERM,Natl Inst Hlth & Med Res,U851, Lyon, France

[3] Univ Lyon 1, F-69365 Lyon, France

[4] Hop Femme Mere Enfant, Bron, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 23期

关键词：

CANCER-THERAPY; PATHWAY; ANTIANGIOGENESIS; VINBLASTINE; SIROLIMUS; INSIGHTS; AGENTS; TARGET;

D O I：

10.1200/JCO.2012.41.7287

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：E213 / E215

页数：3

共 22 条

[1] The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy [J].

Abraham, Robert T. ;

Gibbons, James J. .

CLINICAL CANCER RESEARCH, 2007, 13 (11) :3109-3114

[2] Clinical Insights for Cancer Outcomes in Renal Transplant Patients [J].

Alberu, J. .

TRANSPLANTATION PROCEEDINGS, 2010, 42 (09) :S36-S40

[3] mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy [J].

Baldo, Paolo ;

Cecco, Sara ;

Giacomin, Elisa ;

Lazzarini, Renzo ;

Rose, Barbara ;

Marastoni, Stefano .

CURRENT CANCER DRUG TARGETS, 2008, 8 (08) :647-665

[4] Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis [J].

Bissler, John J. ;

McCormack, Francis X. ;

Young, Lisa R. ;

Elwing, Jean M. ;

Chuck, Gail ;

Leonard, Jennifer M. ;

Schmithorst, Vincent J. ;

Laor, Tal ;

Brody, Alan S. ;

Bean, Judy ;

Salisbury, Shelia ;

Franz, David N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (02) :140-151

[5] Treatment of Childhood Kaposiform Hemangioendothelioma With Sirolimus [J].

Blatt, Julie ;

Stavas, Joseph ;

Moats-Staats, Billie ;

Woosley, John ;

Morrell, Dean S. .

PEDIATRIC BLOOD & CANCER, 2010, 55 (07) :1396-1398

[6]

Flach HZ, 2001, RADIOGRAPHICS, V21, P1311

[7] Vascular tumors and vascular malformations: Evidence for an association [J].

Garzon, MC ;

Enjolras, O ;

Frieden, IJ .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (02) :275-279

[8] Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer [J].

Guba, M ;

Koehl, GE ;

Neppl, E ;

Doenecke, A ;

Steinbauer, M ;

Schlitt, HJ ;

Jauch, KW ;

Geissler, EK .

TRANSPLANT INTERNATIONAL, 2005, 18 (01) :89-94

[9] Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor [J].

Guba, M ;

von Breitenbuch, P ;

Steinbauer, M ;

Koehl, G ;

Flegel, S ;

Hornung, M ;

Bruns, CJ ;

Zuelke, C ;

Farkas, S ;

Anthuber, M ;

Jauch, KW ;

Geissler, EK .

NATURE MEDICINE, 2002, 8 (02) :128-135

[10] The shortened disabilities of the arm, shoulder and hand questionnaire (QuickDASH):: validity and reliability based on responses within the full-length DASH [J].

Gummesson, Christina ;

Ward, Michael M. ;

Atroshi, Isam .

BMC MUSCULOSKELETAL DISORDERS, 2006, 7 (1)

← 1 2 3 →